BI Asset Management Fondsmaeglerselskab A S Purchases 6,029 Shares of Insulet Co. (NASDAQ:PODD)

BI Asset Management Fondsmaeglerselskab A S lifted its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 227.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,674 shares of the medical instruments supplier's stock after acquiring an additional 6,029 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Insulet were worth $2,265,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in PODD. SBI Securities Co. Ltd. bought a new position in shares of Insulet in the fourth quarter worth about $36,000. SRS Capital Advisors Inc. boosted its stake in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after acquiring an additional 56 shares during the period. Friedenthal Financial bought a new position in Insulet during the fourth quarter valued at approximately $57,000. Assetmark Inc. boosted its stake in Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after buying an additional 246 shares during the last quarter. Finally, Blue Trust Inc. boosted its stake in Insulet by 117.3% during the fourth quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock valued at $72,000 after buying an additional 149 shares during the last quarter.

Analyst Ratings Changes

PODD has been the subject of a number of research reports. Canaccord Genuity Group increased their price target on Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Piper Sandler increased their price target on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. StockNews.com lowered Insulet from a "buy" rating to a "hold" rating in a research note on Tuesday, March 4th. Wells Fargo & Company increased their price target on Insulet from $305.00 to $322.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Finally, Royal Bank of Canada started coverage on Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, Insulet presently has an average rating of "Moderate Buy" and an average price target of $292.06.

Insulet Trading Up 0.5 %

PODD traded up $1.33 during trading on Friday, hitting $260.71. 465,388 shares of the stock were exchanged, compared to its average volume of 713,786. The firm has a 50 day simple moving average of $260.21 and a 200 day simple moving average of $261.91. The firm has a market cap of $18.31 billion, a price-to-earnings ratio of 45.03, a P/E/G ratio of 3.62 and a beta of 1.30. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, equities analysts expect that Insulet Co. will post 3.92 EPS for the current year.

Insider Activity

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.47% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.